Scheduling status: S2. Proprietary name (and dosage form): NORFLEX® CO Tablets. Composition: Each tablet contains: 35 mg Orphenadrine citrate and 450 mg Paracetamol. Reference number: B 1098 [Act 101/1965].

Scheduling status: S2. Proprietary name (and dosage form): NORFLEX Tablets. Composition: Each tablet contains 100 mg Orphenadrine citrate. Reference number: H1612. [Act 101/1965].

Scheduling status: S1. Proprietary name and dosage form: NORFLEX Gel. Composition: Each 100g contains: Benzydamine hydrochloride 3,0 g. Registration number: 32/3.1/0547.

Scheduling status: S2 Proprietary name (and dosage form): DURO-TUSS Linctus liquid. Composition: Each 5 mL liquid contains Salbutamol sulphate 2.41 mg; Bromhexine hydrochloride 4 mg. Registration number: A39/10.1/0390.

Scheduling status: S2 Proprietary name (and dosage form): PHOLTEX FORTE liquid. Composition: Each 5 mL liquid contains Pholcodine 15 mg. Registration number: 32/10.1/0116.

Scheduling status: S2 Proprietary name (and dosage form): PHOLTEX JUNIOR syrup. Composition: Each 5 mL liquid contains Pholcodine 5 mg. Registration number: 29/10.1/0013. 

Scheduling status: S2 Proprietary name (and dosage form): PHOLTEX PLUS liquid. Composition: Each 5 mL contains: Pholcodine 5 mg; Phenylephrine hydrochloride 3,3 mg. Registration number: 46/16.5/0711.

Scheduling status: S2. Proprietary name (and dosage form): MetroGel® V vaginal gel. Composition: Metronidazole 37.5 mg/5 g. Registration number: 33/20.2.6/0243.

Scheduling status: S2. Proprietary name (and dosage form): RUPANASE 10 Tablets. Composition: Each tablet contains 12.80 mg rupatadine fumarate equivalent to rupatadine 10 mg base. Registration number: 46/5.7.1/0119.

Scheduling status: S0. Proprietary name (and dosage form): ANDOLEX®-C LOZENGES ORANGE. Composition: Each lozenge contains: Benzydamine HCI 3.00 mg, Cetylpyridinium chloride 1.33 mg. Registration number: 36/16.4/0195.

Scheduling status: S0. Proprietary name (and dosage form): ANDOLEX®-C LOZENGES. Composition: Each lozenge contains: Benzydamine HCl 3.00 mg. Cetylpyridinium chloride 1.33 mg. Registration number: 31/16.4/0042.

Scheduling status: S0. Proprietary name (and dosage form): ANDOLEX®-C LOZENGES HONEY/LEMON. Composition: Each lozenge contains: Benzydamine HCI 3.00 mg, Cetylpyridinium chloride 1.33 mg. Registration number: 35/16.4/0320.

Scheduling status: S0. Proprietary name (and dosage form): ANDOLEX®-C LOZENGES STRAWBERRY. Composition: Each lozenge contains: Benzydamine HCl 3.00 mg. Cetylpyridinium chloride 1.33 mg. Registration number: 33/16.4/0374

Scheduling status: S1. Proprietary name (and dosage form): ANDOLEX®-C Oral Rinse. Composition: Each 15 ml contains: benzydamine HCI 22.5 mg, chlorhexidine gluconate 18 mg, alcohol 9 % v/v. Registration number: 31/16.4/0143.

Scheduling status: S1. Proprietary name (and dosage form): ANDOLEX® solution. Composition: Each 15 ml contains: benzydamine HCI 22.5 mg, alcohol 10 % v/v. Registration number: Z/16/40.

Scheduling status: S1. Proprietary name (and dosage form): ANDOLEX®-C ORAL GEL. Composition: Benzydamine HCI 10 mg/g, cetylpyridinium chloride 1 mg/g. Registration number: 33/16.4/0285.

The claims made in the above are for medical information and educational purposes only. For full prescribing information, refer to the package inserts as approved by SAHPRA (South African Health Products Regulatory Authority).

Proprietary name (and dosage form): ANDOLEX®-C Antibacterial Mouthwash. Composition: Chlorhexidine gluconate 0,12 % m/v; alcohol 9 % v/v. The claims made in this material are for medical information and educational purposes only. For full prescribing information, refer to the individual product packaging.

Proprietary name (and dosage form): ANDOLEX®-C Wildberry Pastilles. Composition: Each 1g pastille contains Ectoin® 10 mg. Classification: Medical Device. The claims made in this material are for medical information and educational purposes only. For full prescribing information, refer to the Instructions For Use.

Proprietary name (and dosage form): Allerguard Allergy Nasal Spray. Classification: Medical device.

Proprietary name (and dosage form): Allerguard Nasal Hygiene. Classification: Medical device.

Proprietary name (and dosage form): Créche Guard Nasal Hygiene Douche. Classification: Medical device.

The claims made in this material are for medical information and educational purposes only. For full prescribing information, refer to the Instructions For Use.

Scheduling status: S1 Proprietary Name (and dosage form): ACITOP cream. Pharmacological Classification: A 20.2.8. Antiviral agent. Composition: Each gram of cream contains 50 mg of Acyclovir. (5.0 % w/w Acyclovir). Preservative: Chlorocresol 0.12 % m/m. Reg. No. 32/20.2.8/0719. Marketed by: iNova Pharmaceuticals (Pty) Limited. Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview. The claims made in the above are for medical information and educational purposes only. For full prescribing information, refer to the package inserts as approved by SAHPRA (South African Health Products Regulatory Authority).

Name and business address of applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15e Riley Road, Bedfordview. Tel. No. 011 087 0000 www.inovapharma.co.za. Further information is available on request from iNova Pharmaceuticals.

Pharmacological Classification: Complementary Medicine: Discipline Specific Traditional Claims D33.6 Western Herbal Medicine. Scheduling Status: S0 Proprietary name (and dosage form): Pholtex Bronchostop® Cough Syrup. Composition: Each 5 ml syrup contains: 39 mg Thyme herb extract and 277 mg Marshmallow root dry extract.

Pharmacological Classification: Complementary Medicine:

Discipline Specific Traditional Claims D33.6 Western Herbal Medicine. Scheduling Status: S0 Proprietary name (and dosage form): Pholtex Bronchostop® Cough Pastilles. Composition: Each pastille contains: 51.1 mg Thyme herb extract and 4.5 mg Marshmallow root dry extract.

Proprietary name (and dosage form): Pholtex Bronchostop® Children’s Cough Syrup. Composition: Each 5 ml syrup contains: 48 mg Marshmallow root dry extract and 250 mg Honey.

These unregistered medicines have not been evaluated by the SAHPRA for their quality, safety or intended use. For full prescribing information, refer to the individual professional information or instructions for use. Further information is available on request from

iNova Pharmaceuticals. Name and business address of applicant: iNova Pharmaceuticals (Pty) Limited. Co. Reg. No. 1952/001640/07, 15e Riley Road, Bedfordview. Tel. No. 011 087 0000. www.inovapharma.co.za. IN4541/22